Get the Daily Brief
Latest Biotech News
Regulatory and evidence updates for diagnostics and tumor-agnostic oncology
Two new companion-diagnostic validations support broader pembrolizumab eligibility in dMMR/MSI-H solid tumors, with post-marketing bridging data confirming that two commercially available...
Phase 3 and higher evidence reshaping cancer and radiation strategies
In advanced hepatocellular carcinoma, proton therapy failed to deliver a survival benefit in the Phase III NRG-GI003 trial, which was stopped early for futility. The results reinforce that...
Immuno-oncology biomarkers and translational ex vivo testing
A Lund University-led ex vivo model suggests that precision-cut bladder tumor slices can preserve immune cells and remain functional for up to six days, enabling drug testing that reproduced...
Molecular drivers of therapy resistance and immune evasion in cancer
New mechanistic work ties gene regulation and immune escape to real resistance phenotypes. A study reports that DNA methylation silences components of the TRAIL apoptosis pathway—DR5, DcR2 and...
Drug safety, toxicity, and precision risk signals across clinical care
A new analysis in pharmacovigilance reports that liver injury after CAR T-cell therapy often tracks with cytokine release syndrome timing, with an early-onset signal dominating. The dataset also...
Evidence on imaging and AI-driven patient selection for oncology
Machine learning continues to move from retrospective performance toward tools that can influence patient pathways. A multicenter study reports that CT-based radiomics can noninvasively predict...
NICU care practices: revisiting rooming strategies
A randomized trial of 85 very preterm infants found no difference in death or neurodevelopmental impairment at 36 months between single-family room and open-bay NICU care. Despite the lack of...
Pediatric and maternal care: precision dosing and clinical trial evidence
A Vietnamese cohort study suggests a simplified fixed-dose follitropin delta regimen can match standard approaches for live birth in IVF freeze-all cycles, with shorter stimulation durations and...
Technology transfer and formulation science moving toward the clinic
The Journal of Pharmaceutical Investigation announced a January 2027 special issue focused on translational advances in pharmaceutical dosage form development, emphasizing particle engineering,...
Major funding and corporate deal activity in biotech
Viatris will acquire Pacira BioSciences in a $1.65 billion transaction, agreeing to buy all outstanding Pacira shares for $36.50 each in cash. The deal brings a pain-care portfolio platform into...
Regulatory-validated diagnostics for tumor-agnostic oncology
Post-marketing bridging data are validating companion diagnostics used to identify eligible patients for pembrolizumab in dMMR/MSI-H solid tumors. Merck & Co. reported results in BMC Cancer...
New imaging marker for brain metastasis radiosurgery outcomes
A Phase 3 trial reports a major reduction in recurrence after brain metastasis surgery with implantation of cesium-131 collagen tiles. Compared with standard postoperative radiation, recurrence at...
Carving out safer and more scalable IVF protocols
A randomized trial involving 300 women found that an IVF ovarian stimulation protocol that skips GnRH antagonist injections early in the follicular phase produced similar numbers of usable...
Translational particle engineering for drug formulation
The Journal of Pharmaceutical Investigation announced a January 2027 special issue focused on translational advances in pharmaceutical dosage form development via particle engineering and...
FDA-cleared rapid diagnostic for invasive aspergillosis
Johns Hopkins Medicine published clinical validation data supporting the first FDA-cleared rapid urine test for invasive aspergillosis. The result adds a point-of-care compatible specimen pathway...
Clinical trial signal: enhanced lung cancer management via immune-guided blood testing
A study in Cancer Discovery proposes that a blood-based approach combining circulating tumor DNA and immune cell readouts can identify cancer neoantigens and reactive T cells without a tissue...
Targeting TNF survival biology with a new molecular switch
Researchers identified HERC4 as a critical molecular switch converting TNF survival signaling into cell death. The finding links TNF pathway biology to druggable targets and opens an oral-therapy...
Oncology immunobiology: MDA5 turns immune evasion into a druggable vulnerability
Nature Communications reports that the viral RNA sensor MDA5 helps tumors evade immune attack. Disabling MDA5 triggered immunogenic cell death and increased CD8-positive T-cell responses, with...
Cancer resistance and metabolism: leflunomide reverses SMARCD1-driven kidney tumor mitochondrial changes
A Nature Communications study shows that loss of the SWI/SNF subunit SMARCD1 reprograms clear cell renal cell carcinoma mitochondria via a MAFF–MFN1 pathway. Importantly, the approved drug...
AI-accelerated design of RNA therapeutics using an automated lipid nanoparticle platform
MIT chemical engineers unveiled an automated, self-correcting platform that rapidly produces lipid nanoparticles with precisely controlled sizes and shapes. The system aims to accelerate RNA...